Skip to main content

As with many other substances, a patient’s use of marijuana, both medically and recreationally, can impact physical therapy outcomes.

We have a lot yet to learn, and many issues are in flux: State laws and regulations around medical and recreational use are changing, making it imperative to understand what is and isn't permitted in your state. Similarly, FDA Controlled Substance Act classifications around the variety of products derived from cannabis and cannabinoids can be complex, with drug classifications ranging from Schedule I to Schedule V. To date, there is not enough data to make recommendations for the clinical use of topical cannabinoids.

Though our understanding is evolving, information is increasingly available as use becomes more and more common. Here are some resources that can help you gain perspective on the issue.

Log in or create a free account to keep reading.

Join APTA to get unlimited access to content.

You Might Also Like...


Landmark APTA Report Makes the Case for Physical Therapy's Economic Value

Sep 27, 2023

The macroeconomic review of eight conditions shows how physical therapy delivers cost-effectiveness through quality-of-life improvements.


Faster Therapy Start Decreases Risk for Future Opioid Use in Knee OA Patients

Aug 7, 2023

Researchers found delayed treatment increased risks that ranged from 25% to 150% depending on timing of the first visit.


From PTJ: Psychologically Informed Practice and a 'Roadmap' for Implementation

Jun 13, 2023

In companion articles, authors explore the drivers of PiP and offer a model for its use with patients experiencing chronic pain.